Matrix metalloproteinases in thoracic aortic aneurysm disease

International Journal of Angiology

Volumn 15, Issue 1, 2006, Pages 1-8

  Botta, Donald ^a   Elefteriades, John A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ABDOMINAL AORTA ANEURYSM; ANEURYSM RUPTURE; ANEURYSM SURGERY; AORTA WALL; ENZYME BLOOD LEVEL; ENZYME SYNTHESIS; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MONITORING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THORACIC AORTA ANEURYSM;

EID: 33749825668     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-006-2080-z     Document Type: Review

References (106)

1. Clouse WD, Hallett JW Jr, Schaff HV, Gayari MM, Ilstrup DM, Melton LJ III (1998) Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA 280(22):1926-1929.
2. Clouse WD, Hallett JW Jr, Schaff HV, Spittell PC, Rowland CM, Ilstrup DM, Melton LJ III (2004) Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc 79(2):176-180.
3. Johansson G, Markstrom U, Swedenborg J (1995) Ruptured thoracic aortic aneurysms: a study of incidence and mortality rates. J Vasc Surg 21(6):985-988.
4. Centers for Disease Control and Prevention: National Center for Health Statistics, National Hospital Discharge Survey; 2001, Table 42.
5. Miller CC III, Porat EE, Estrera AL, Vinnerkvist AN, Huynh TT, Safi HJ (2004) Number needed to treat: analyzing of the effectiveness of thoracoabdominal aortic repair. Eur J Vasc Endovasc Surg 28(2):154-157.
6. Rizzo JA, Coady MA, Elefteriades JA (1998) Procedures for estimating growth rates in thoracic aortic aneurysms. J Clin Epidemiol 51(9):747-754.
7. Rizzo JA, Coady MA, Elefteriades JA (1999) Interpreting data on thoracic aortic aneurysms. Statistical issues. Cardiol Clin 17(4):797-805.
8. Coady MA, Rizzo JA, Elefteriades JA (1999) Developing surgical intervention criteria for thoracic aortic aneurysms. Cardiol Clin 17(4):827-839.
9. Elefteriades JA (2002) Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 74(5):S1877-S1880; discussion S1892-S1898.
10. Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B, Coe MP, Kopf GS, Elefteriades JA (2006) Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 81(1):169-177.
11. Koullias G, Modak R, Tranquilli M, Korkolis DP, Barash P, Elefteriades JA (2005) Mechanical deterioration underlies malignant behavior of aneurysmal human ascending aorta. J Thorac Cardiovasc Surg 130(3):677-683.
12. Coady MA, Davies RR, Roberts M, Goldstein LJ, Rogalski MJ, Rizzo JA, Hammond GL, Kopf GS, Elefteriades JA (1999) Familial patterns of thoracic aortic aneurysms. Arch Surg 134(4):361-367.
13. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, Elefteriades JA (2002) Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 73(1):17-27; discussion 27-28.
14. Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, Kopf GS, Elefteriades JA (2001) Stroke in surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac Cardiovasc Surg 122(5):935-945.
15. Ikonomidis JS, Gibson WC, Gardner J, Sweterlitsch S, Thompson RP, Mukherjee R, Spinale FG (2003) A murine model of thoracic aortic aneurysms. J Surg Res 115(1):157-163.
16. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P (1995) Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 92(2):402-406.
17. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, Heinecke J, Humphrey JD, Kuivaniemi H, Parks WC, Pearce WH, Platsoucas CD, Sukhova GK, Thompson RW, Tilson MD, Zarins CK (2001) Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 34(4):730-738.
18. Davies MJ (1998) Aortic aneurysm formation: lessons from human studies and experimental models. Circulation 98(3):193-195.
19. Lemaitre V, Soloway PD, D'Armiento J (2003) Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 107(2):333-338.
20. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT (1995) Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15(8):1145-1151.
21. Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapiere CM (1996) Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 24(1):127-133.
22. Petersen E, Wagberg F, Angquist KA (2002) Proteolysis of the abdominal aortic aneurysm wall and the association with rupture. Eur J Vasc Endovasc Surg 23(2):153-157.
23. Petersen E, Gineitis A, Wagberg F, Angquist KA (2000) Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 20(5):457-461.
24. Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3(3):207-214.
25. Makela M, Salo T, Uitto VJ, Larjava H (1994) Matrix metalloproteinases (MMP-2 and MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. J Dent Res 73(8):1397-1406.
26. Lee RT (2001) Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc Med 11(5):202-205.
27. Spinale FG (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90(5):520-530.
28. Spinale FG (2004) Matrix metalloproteinase gene polymorphisms in heart failure: new pieces to the myocardial matrix puzzle. Eur Heart J 25(8):631-633.
29. Islam MM, Franco CD, Courtman DW, Bendeck MP (2003) A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am J Pathol 163(4):1557-1566.
30. Sho E, Chu J, Sho M, Fernandes B, Judd D, Ganesan P, Kimura H, Dalman RL (2004) Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 39(6):1312-1321.
31. Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A (2000) Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol 20(12):E120-E126.
32. Ramamurthy NS, McClain SA, Pirila E, Maisi P, Salo T, Kucine A, Sorsa T, Vishram F, Golub LM (1999) Wound healing in aged normal and ovariectomized rats: effects of chemically modified doxycycline (CMT-8) on MMP expression and collagen synthesis. Ann NY Acad Sci 878:720-723.
33. Carney DE, Lutz CJ, Picone AL, Gatto LA, Ramamurthy NS, Golub LM, Simon SR, Searles B, Paskanik A, Snyder K, Finck C, Schiller HJ, Nieman GF (1999) Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation 100(4):400-406.
34. Gapski R, Barr JL, Sarment DP, Layher MG, Socransky SS, Giannobile WV (2004) Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial. J Periodontol 75(3):441-452.
35. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH (2004) Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. J Clin Periodontol 31(9):697-707.
36. Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H (2004) The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 75(1):106-115.
37. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E (2001) Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 19(2):584-592.
38. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW (2000) Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105(11):1641-1649.
39. Ikonomidis JS, Barbour JR, Amani Z, Stroud RE, Herron AR, McClister DM Jr, Camens SE, Lindsey ML, Mukherjee R, Spinale FG (2005) Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 112(9 suppl):I242-I248.
40. Ikonomidis JS, Gibson WC, Butler JE, McClister DM, Sweterlitsch SE, Thompson RP, Mukherjee R, Spinale FG (2004) Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation 110(11 suppl 1):II268-II273.
41. Kaito K, Urayama H, Watanabe G (2003) Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today 33(6):426-433.
42. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW (1998) Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 28(6):1082-1093.
43. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, Baxter BT (2002) Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of plasma levels and effect on aneurysm growth in mice. J Vasc Surg 35(5):923-929.
44. Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, Sicard GA, Thompson RW (2000) Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 31(2):325-342.
45. Kadoglou NP, Liapis CD (2004) Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin 20(4):419-432.
46. Thompson RW, Baxter BT (1999) MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 878:159-178.
47. Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RW (2000) Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 11(10):1345-1352.
48. Tamarina NA, McMillan WD, Shively VP, Pearce WH (1997) Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 122(2):264-271; discussion 271-272.
49. Gadson PF Jr, Dalton ML, Patterson E, Svoboda DD, Hutchinson L, Schram D, Rosenquist TH (1997) Differential response of mesoderm- and neural crest-derived smooth muscle to TGFbeta1: regulation of c-myb and alpha1 (I) procollagen genes. Exp Cell Res 230(2):169-180.
50. Wedding KL, Draney MT, Herfkens RJ, Zarins CK, Taylor CA, Pelc NJ (2002) Measurement of vessel wall strain using cine phase contrast MRI. J Magn Reson Imaging 15(4):418-428.
51. Chew DK, Knoetgen J III, Xia S, Gaetz HP, Tilson MD (1999) Regional distribution in human of a novel aortic collagen-associated microfibrillar protein. Exp Mol Pathol 66(1): 59-65.
52. Rao RN, Falls DG, Gerrity RG, Sethuraman SN, Thiruvaiyaru DS (2000) Intimal thickness and layering, and smooth muscle cell phenotypes in aorta of youth. Pathobiology 68(1):18-28.
53. Kazi M, Zhu C, Roy J, Paulsson-Berne G, Hamsten A, Swedenborg J, Hedin U, Eriksson P (2005) Difference in matrix-degrading protease expression and activity between thrombusfree and thrombus-covered wall of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 25(7):1341-1346.
54. Absi TS, Sundt TM III, Tung WS, Moon M, Lee JK, Damiano RR Jr, Thompson RW (2003) Altered patterns of gene expression distinguishing ascending aortic aneurysms from abdominal aortic aneurysms: complementary DNA expression profiling in the molecular characterization of aortic disease. J Thorac Cardiovasc Surg 126(2):344-357; discussion 357.
55. Koulias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades JA (2004) Increased tissue microarray MMP expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 78(6):2106-2110; discussion 2110-2111.
56. McMillan WD, Pearce WH (1999) Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 29(1):122-127; discussion 127-129.
57. Sinha I, Bethi S, Cronin P, Williams DM, Roelofs K, Ailawadi G, Henke PK, Eagleton MJ, Deeb GM, Patel HJ, Berguer R, Stanley JC, Upchurch GR Jr (2006) A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2. J Vasc Surg 43(2):342-348.
58. Fedak PW, Sa MPde , Verma S, Nili N, Kazemian P, Butany J, Strauss BH, Weisel RD, David TE (2003) Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 126(3):797-806.
59. Boyum J, Fellinger EK, Schmoker JD, Trombley L, McPartland K, Ittleman FP, Howard AB (2004) Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves. J Thorac Cardiovasc Surg 127(3):686-691.
60. Lesauskaite V, Tanganelli P, Sassi C, Neri E, Diciolla F, Ivanoviene L, Epistolato MC, Lalinga AV, Alessandrini C, Spina D (2001) Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol 32(9):1003-1011.
61. Taketani T, Imai Y, Morota T, Maemura K, Morita H, Hayashi D, Yamazaki T, Nagai R, Takamoto S (2005) Altered patterns of gene expression specific to thoracic aortic aneurysms: microarray analysis of surgically resected specimens. Int Heart J 46(2):265-277.
62. Shores J, Berger KR, Murphy EA, Pyeritz RE (1994) Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 330(19):1335-1341.
63. Mills SE, Teja K, Crosby IK, Sturgill BC (1979) Aortic dissection: surgical and nonsurgical treatments compared. An analysis of seventy-four cases at the University of Virginia. Am J Surg 137(2):240-243.
64. Wheat MW Jr, Palmer RF, Bartley TD, Seelman RC (1965) Treatment of dissecting aneurysms of the aorta without surgery. J Thorac Cardiovasc Surg 50:364-373.
65. Lindholt JS, Henneberg EW, Juul S, Fasting H (1999) Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 18(1):52-57.
66. White SR, Hall JB (1985) Control of hypertension with nifedipine in the setting of aortic dissection. Chest 88(5):780-781.
67. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA, Scott AP, Quick CR (2002) Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 36(4):751-757.
68. Boyle JR, Loftus IM, Goodall S, Crowther M, Bell PR, Thompson MM (1998) Amlodipine potentiates metalloproteinase activity and accelerates elastin degradation in a model of aneurysmal disease. Eur J Vasc Endovasc Surg 16(5):408-414.
69. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL (2000) Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 101(17):2103-2109.
70. Moon SK, Cha BY, Kim CH (2004) ERK1/2 mediates TNFalpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: Involvement of the ras dependent pathway. J Cell Physiol 198(3):417-427.
71. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, Saikku P, Juvonen T (2001) Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 34(4):606-610.
72. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117-121.
73. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE (1993) Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 90(10):4577-4581.
74. Varon C, Tatin F, Moreau V, Van Obberghen-Schilling E, Fernandez-Sauze S, Reuzeau E, Kramer I, Genot E (2006) Transforming growth factor beta induces rosettes of podosomes in primary aortic endothelial cells. Mol Cell Biol 26(9):3582-3594.
75. Lesauskaite V, Tanganelli P, Sassi C, Neri E, Diciolla F, Ivanoviene L, Epistolato MC, Lalinga AV, Alessandrini C, Spina D (2001) Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol 32(9):1003-1011.
76. Tang PC, Coady MA, Lovoulos C, Dardik A, Aslan M, Elefteriades JA, Tellides G (2005) Hyperplastic cellular remodeling of the media in ascending thoracic aortic aneurysms. Circulation 112(8):1098-1105.
77. Lee T, Esemuede N, Sumpio BE, Gahtan V (2003) Thrombospondin-1 induces matrix metalloproteinase-2 activation in vascular smooth muscle cells. J Vasc Surg 38(1):147-154.
78. Dixon IM, Hao J, Reid NL, Roth JC (2000) Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 46(2):286-297.
79. Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, Vatner SF, Lakatta EG (2003) Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 41(6):1308-1316.
80. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J (2005) Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111(23):3119-3125.
81. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D, Cheng L, Krawczyk M, Talan M, Pintus G, Lakatta EG (2005) Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 167(5):1429-1442.
82. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H (2004) Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 44(2):362-368.
83. Chen H, Li D, Mehta JL (2002) Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 39(3):332-339.
84. Liang C, Wu ZG, Ding J, Jiang JF, Huang GZ, Du RZ, Ge JB (2004) Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol Sin 25(11):1426-1432.
85. Moon MC, Molnar K, Yau L, Zahradka P (2004) Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. J Vasc Surg 40(1):130-137.
86. Claridge MW, Hobbs SD, Quick CR, Day NE, Bradbury AW, Wilmink AB (2004) ACE inhibitors increase type III collagen synthesis: a potential explanation for reduction in acute vascular events by ACE inhibitors. Eur J Vasc Endovasc Surg 28(1):67-70.
87. Kalyanasundaram A, Elmore JR, Manazer JR, Golden A, Franklin DP, Galt SW, Zakhary EM, Carey DJ (2006) Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 43(1):117-124.
88. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H (2002) A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 36(1):158-163.
89. Armstrong PJ, Franklin DP, Carey DJ, Elmore JR (2005) Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg 19(2):248-257.
90. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM (1999) Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 29(5):884-892; discussion 892-893.
91. Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM (1996) Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 63(1):305-309.
92. Sinha I, Hannawa KK, Ailawadi G, Woodrum DT, Ford JW, Henke PK, Stanley JC, Eagleton MJ, Upchurch GR Jr (2006) The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 20(1):92-98.
93. Moore G, Liao S, Curci JA, Starcher BC, Martin RL, Hendricks RT, Chen JJ, Thompson RW (1999) Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg 29(3):522-532.
94. Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PR, Thompson MM (1999) Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg 86(8):1053-1058.
95. Prescott MF, Sawyer WK, Linden-Reed JVon , Jeune M, Chou M, Caplan SL, Jeng AY (1999) Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann NY Acad Sci 878:179-190.
96. Parodi FE, Mao D, Ennis TL, Bartoli MA, Thompson RW (2005) Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg 41(3):479-489.
97. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR (1999) The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 29(1):130-138; discussion 138-139.
98. Nagashima H, Aoka Y, Sakomura Y, Uto K, Sakuta A, Aomi S, Kurosawa H, Hagiwara N, Kawana M, Kasanuki H (2004) Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg 39(2):447-453.
99. Kanai K, Asano K, Hisamitsu T, Suzaki H (2004) Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediators Inflamm 13(5-6):313-319.
100. Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW (2002) Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 88(8):1066-1072Erratum in: Br J Surg 89(1):120-121.
101. van Marle S, van Vliet A, Sollie F, Kambayashi Y, Yamada-Sawada T (2005) Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther 43(6):282-293.
102. Lawrence DM, Singh RS, Franklin DP, Carey DJ, Elmore JR (2004) Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 40(2):334-338.
103. Albornoz G, Coady MA, Roberts M, et al. (2006) Familial thoracic aneurysms and dissections - Incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg (in press).
104. Wang Y, Barbacioru CC, Schiffman D, et al. (2006) Gene expression signature of peripheral blood for diagnosis of aortic aneurysm. Molecular Tri-Conference. San Francisco.
105. Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG, McAllister HA Jr, Willerson JT, Ferrans VJ (1998) Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 98(19 suppl):II331-II337; discussion II337-II338.
106. Nataatmadja M, West M, West J, Summers K, Walker P, Nagata M, Watanabe T (2003) Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 108 (suppl 1):II329-II334.